# Safety Outcomes of Lower Immunosuppression Versus Traditional Immunosuppression in Heart Transplant Recipients

> **NCT00299221** · PHASE4 · COMPLETED · sponsor: **Newark Beth Israel Medical Center** · enrollment: 150 (actual)

## Conditions studied

- Immunosuppression

## Interventions

- **DRUG:** Tacrolimus
- **DRUG:** combination therapy

## Key facts

- **NCT ID:** NCT00299221
- **Lead sponsor:** Newark Beth Israel Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2009-06
- **Final completion:** 2009-12
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2015-05-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00299221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00299221, "Safety Outcomes of Lower Immunosuppression Versus Traditional Immunosuppression in Heart Transplant Recipients". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00299221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*